The funding will enable OSSTEC to complete regulatory approval in the US and train surgeons in using the new technology, paving the way for the first US surgical cases involving its innovative joint replacements from next year.
Dr Max Munford, Founder and Chief Executive of OSSTEC, stated, "This financing moves our focus from preparation to patients. Surgeons tell us they would offer a partial knee to more patients if they could use next-generation cementless technology. Ascent is designed to give them that, integrated with a familiar, streamlined surgical workflow."
Partial knee implants offer a bone-preserving procedure with faster recovery, yet only about 10 per cent of suitable patients receive one. OSSTEC's cementless implants aim to reduce complexity and the risk of loosening, which often requires further surgery.
The company is also exploring new applications for its technology, with a pipeline of cementless applications beyond the knee and potential integration with robotic surgery platforms.
Founded in 2021 based on Dr Munford's PhD research, OSSTEC has benefited from support through Imperial's Enterprise Lab programmes. The company previously raised £1.2 million in seed funding in 2023 and £2.5 million in 2025.
The latest investment round was led by Embryo Ventures, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance, and Empirical Ventures. Dr Arash Moavenian, Chief Executive of Embryo Ventures, commented, "We are excited to lead this financing round in OSSTEC, representing an exceptional opportunity to advance partial knee replacement."
